1308917-77-2

Upstream product

• 101226-42-0 1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carbaldehyde 
• 15250-46-1 ethyl (4-iodophenyl)acetate 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 626604-89-5 [1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-acetonitrile 
• 859169-20-3 1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetic acid ethyl ester 
• 1308917-74-9 2-amino-7-chloro-1-ethyl-3-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-1H-[1,8]naphthyridin-4-one 
• 1092523-21-1 6-chloro-2-(ethylamino)pyridine-3-carboxylic acid 
• 1092523-22-2 6-chloro-2-(ethylamino)pyridine-3-carbonyl fluoride 
• 1308917-78-3 C₂₉H₃₇N₅O₄Si 

Downstream Products

• 1308917-80-7 2-{4-[7-amino-8-ethyl-5-oxo-6-(1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)-5,8-dihydro-1,8-naphthyridin-2-yl]phenyl}-N-[(4-cyclopropylmorpholin-3-yl)methyl]acetamide 

Relevant academic research and scientific papers

PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

The present invention relates to derivatives of pyridino-pyridinones, and to their preparation and use thereof, having activity as inhibitors of kinase activity of receptors for PDGF (platelet derived growth factors) ligands and optionally of receptors for the FLT3 (fms-like tyrosine kinase receptor) ligand receptors, said derivatives comprising compounds of formula (I): wherein the various substituent groups are more specifically defined herein. The compounds are suitable as therapeutics for the treatment of various proliferative diseases.